ALK-Abelló A/S (AKBLF)
USD 21.35
(-4.47%)
USD 21.35
(-4.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 666 Million DKK | 41.7% |
| 2022 | 470 Million DKK | 60.96% |
| 2021 | 292 Million DKK | 94.67% |
| 2020 | 150 Million DKK | 1171.43% |
| 2019 | -14 Million DKK | 85.42% |
| 2018 | -96 Million DKK | -20.0% |
| 2017 | -80 Million DKK | -116.7% |
| 2016 | 479 Million DKK | 64.04% |
| 2015 | 292 Million DKK | 10.61% |
| 2014 | 264 Million DKK | 142.2% |
| 2013 | 109 Million DKK | -7.63% |
| 2012 | 118 Million DKK | -60.54% |
| 2011 | 299 Million DKK | 55.73% |
| 2010 | 192 Million DKK | 9.71% |
| 2009 | 175 Million DKK | 47.06% |
| 2008 | 119 Million DKK | -45.41% |
| 2007 | 218 Million DKK | 311.32% |
| 2006 | 53 Million DKK | 2550.0% |
| 2005 | 2 Million DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 262 Million DKK | -17.09% |
| 2024 Q1 | 316 Million DKK | 62.89% |
| 2023 Q3 | 147 Million DKK | 51.55% |
| 2023 Q2 | 97 Million DKK | -57.46% |
| 2023 Q1 | 228 Million DKK | 65.22% |
| 2023 FY | 666 Million DKK | 41.7% |
| 2023 Q4 | 194 Million DKK | 31.97% |
| 2022 FY | 470 Million DKK | 60.96% |
| 2022 Q3 | 68 Million DKK | 38.78% |
| 2022 Q1 | 215 Million DKK | 172.15% |
| 2022 Q2 | 49 Million DKK | -77.21% |
| 2022 Q4 | 138 Million DKK | 102.94% |
| 2021 Q3 | 55 Million DKK | 787.5% |
| 2021 FY | 292 Million DKK | 94.67% |
| 2021 Q4 | 79 Million DKK | 43.64% |
| 2021 Q2 | -8 Million DKK | -104.82% |
| 2021 Q1 | 166 Million DKK | 1944.44% |
| 2020 Q3 | 6 Million DKK | -62.5% |
| 2020 FY | 150 Million DKK | 1171.43% |
| 2020 Q1 | 137 Million DKK | 1470.0% |
| 2020 Q2 | 16 Million DKK | -88.32% |
| 2020 Q4 | -9 Million DKK | -250.0% |
| 2019 FY | -14 Million DKK | 85.42% |
| 2019 Q3 | -18 Million DKK | 70.97% |
| 2019 Q4 | -10 Million DKK | 44.44% |
| 2019 Q2 | -62 Million DKK | -181.58% |
| 2019 Q1 | 76 Million DKK | 193.83% |
| 2018 Q1 | 47 Million DKK | 133.81% |
| 2018 FY | -96 Million DKK | -20.0% |
| 2018 Q3 | -9 Million DKK | 75.68% |
| 2018 Q2 | -37 Million DKK | -178.72% |
| 2018 Q4 | -81 Million DKK | -800.0% |
| 2017 FY | -80 Million DKK | -116.7% |
| 2017 Q4 | -139 Million DKK | -1444.44% |
| 2017 Q3 | -9 Million DKK | 67.86% |
| 2017 Q2 | -28 Million DKK | -129.17% |
| 2017 Q1 | 96 Million DKK | 74.55% |
| 2016 Q2 | 119 Million DKK | -49.58% |
| 2016 Q4 | 55 Million DKK | -20.29% |
| 2016 Q3 | 69 Million DKK | -42.02% |
| 2016 FY | 479 Million DKK | 64.04% |
| 2016 Q1 | 236 Million DKK | 126.92% |
| 2015 Q4 | 104 Million DKK | -16.13% |
| 2015 Q1 | 91 Million DKK | 378.95% |
| 2015 Q2 | -27 Million DKK | -129.67% |
| 2015 FY | 292 Million DKK | 10.61% |
| 2015 Q3 | 124 Million DKK | 559.26% |
| 2014 Q4 | 19 Million DKK | 5.56% |
| 2014 FY | 264 Million DKK | 142.2% |
| 2014 Q3 | 18 Million DKK | -66.04% |
| 2014 Q2 | 53 Million DKK | -69.54% |
| 2014 Q1 | 174 Million DKK | 180.65% |
| 2013 Q2 | -40 Million DKK | -157.14% |
| 2013 FY | 109 Million DKK | -7.63% |
| 2013 Q3 | 17 Million DKK | 142.5% |
| 2013 Q1 | 70 Million DKK | 3400.0% |
| 2013 Q4 | 62 Million DKK | 264.71% |
| 2012 Q3 | 99 Million DKK | 283.33% |
| 2012 Q2 | -54 Million DKK | -176.06% |
| 2012 Q1 | 71 Million DKK | 407.14% |
| 2012 Q4 | 2 Million DKK | -97.98% |
| 2012 FY | 118 Million DKK | -60.54% |
| 2011 Q4 | 14 Million DKK | -41.67% |
| 2011 Q2 | -6 Million DKK | -102.76% |
| 2011 Q3 | 24 Million DKK | 500.0% |
| 2011 Q1 | 217 Million DKK | 189.33% |
| 2011 FY | 299 Million DKK | 55.73% |
| 2010 FY | 192 Million DKK | 9.71% |
| 2010 Q3 | 24 Million DKK | 500.0% |
| 2010 Q1 | 114 Million DKK | 165.12% |
| 2010 Q4 | 75 Million DKK | 212.5% |
| 2010 Q2 | -6 Million DKK | -105.26% |
| 2009 FY | 175 Million DKK | 47.06% |
| 2009 Q4 | 43 Million DKK | -6.52% |
| 2009 Q3 | 46 Million DKK | 866.67% |
| 2009 Q2 | -6 Million DKK | -107.79% |
| 2009 Q1 | 77 Million DKK | 0.0% |
| 2008 FY | 119 Million DKK | -45.41% |
| 2007 FY | 218 Million DKK | 311.32% |
| 2006 FY | 53 Million DKK | 2550.0% |
| 2005 FY | 2 Million DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | 53125.478% |
| Skye Bioscience, Inc. | -13.67 Million USD | 4971.341% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -713.665% |
| Nascent Biotech, Inc. | -2.22 Million USD | 29967.091% |
| Qrons Inc. | -643.67 Thousand USD | 103568.044% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 8661.546% |
| CSL Limited | 3.7 Billion USD | 82.01% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 3831.72% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 13302.542% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 97050.288% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 1299.827% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 160396.91% |
| Rebus Holdings, Inc. | -664 Thousand USD | 100401.205% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 49971.54% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 171057.723% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 4296.667% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 1027.758% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -13450.877% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 254564.593% |
| SQZ Biotechnologies Company | -75.82 Million USD | 978.338% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 23464.265% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 43457.992% |
| Mesoblast Limited | -84.14 Million USD | 891.472% |
| Marizyme, Inc. | -34.08 Million USD | 2053.852% |
| Genus plc | 6.4 Million USD | -10306.25% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -6736.056% |
| Pharming Group N.V. | -4.87 Million USD | 13748.816% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 33626.657% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 71606.796% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 8076.048% |
| ContraFect Corporation | -56.88 Million USD | 1270.701% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 14722.175% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 47603.871% |
| IMV Inc. | -38.67 Million USD | 1822.198% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 24310.795% |
| MultiCell Technologies, Inc. | -722.81 USD | 92140496.508% |
| ONE Bio Corp. | 13.68 Million USD | -4767.87% |
| Accustem Sciences Inc. | -3.74 Million USD | 17876.976% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 1229.005% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 137970.501% |
| Q BioMed Inc. | -3.44 Million USD | 19428.91% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -18713.559% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 25447.076% |
| Biomind Labs Inc. | -1 Million USD | 66066.523% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 1311.518% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 23055.623% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 10118.028% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 35822.523% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 2223657.692% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 34561.169% |
| GB Sciences, Inc. | -1.42 Million USD | 46984.603% |
| Alpha Cognition Inc. | -9.7 Million USD | 6962.017% |
| HST Global, Inc. | -140.9 Thousand USD | 472752.175% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 59304.947% |
| Halberd Corporation | -75.05 Thousand USD | 887508.394% |
| Enzolytics Inc. | -2.14 Million USD | 31094.043% |
| Agentix Corp. | -1.37 Million USD | 48650.908% |
| Resverlogix Corp. | -12.74 Million USD | 5323.939% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 21120.909% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 256.688% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 63893.103% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 22912.563% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 42269.113% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 19659.592% |
| AVAX Technologies, Inc. | 6.69 Million USD | -9850.873% |
| Zenith Capital Corp. | -8.94 Million USD | 7547.165% |
| Genscript Biotech Corporation | -415.79 Million USD | 260.177% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 3823072.275% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 27224.807% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 388416.592% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 33320.984% |
| Kadimastem Ltd | -3.04 Million USD | 22006.093% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 67779.282% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 367072.477% |
| LadRx Corporation | -3.82 Million USD | 17518.022% |
| Cell Source, Inc. | -4.32 Million USD | 15497.612% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 97050.288% |
| NovAccess Global Inc. | -2.46 Million USD | 27098.978% |
| Affymax, Inc. | -15.04 Million USD | 4526.426% |
| Itoco Inc. | -919.14 Thousand USD | 72559.038% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 15813.425% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 59617.426% |
| Mobile Lads Corp. | -554.55 Thousand USD | 120197.376% |
| CytoDyn Inc. | -18.05 Million USD | 3788.116% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 2646107.151% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 302719.98% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 118033.925% |
| SYBLEU INC | -149.18 Thousand USD | 446540.542% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 36767.548% |
| International Stem Cell Corporation | -663 Thousand USD | 100552.489% |
| Bioxytran, Inc. | -3.82 Million USD | 17533.884% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 1265297.568% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 3274436.283% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 1936.431% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 41261.928% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 90609.421% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 21507.907% |
| Neutra Corp. | -229.48 Thousand USD | 290313.782% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 3897.252% |
| PureTech Health plc | -146.19 Million USD | 555.543% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 3198.954% |
| IXICO plc | -1.43 Million USD | 46446.555% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 7117.174% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 646.771% |
| CSL Limited | 3.81 Billion USD | 82.529% |
| Cellectis S.A. | -108.85 Million USD | 711.81% |